The Epic Pass Added Six Large Austrian Ski Resorts in the Past Week

For Vail Resorts' multi-mountain pass, the Epic Pass, last week was big. Six additional Austrian resorts have been added to the Epic Pass coverage ahead of the 2025-2026 ski season, including Sölden, Silvretta Montafon, Mayrhofen, Hintertux, Saalbach, and Kitzsteinhorn. The fast-paced announcements began Wednesday, May 21, when Vail Resorts first shared in a press release that Saalbach and Kitzsteinhorn would become Epic Pass partner destinations. The latest Vail Resorts announcement, which regarded Sölden, came over the long weekend.At the new destinations, Epic Pass holders will have five days of consecutive or non-consecutive access, depending on the mountain. (In the case of two resort pairings—Mayrhofen and Hintertux, Saalbach and Kitzsteinhorn—the five days are shared).Want to keep up with the best stories and photos in skiing? Subscribe to the new Powder To The People newsletter for weekly updates.
'We're proud to join the Epic Pass and open Sölden to a new global audience,' said Jakob Falkner, CEO of Bergbahnen Sölden, in a press release. 'This partnership brings together innovation, alpine heritage, and our passion for unforgettable mountain experiences—while showcasing Sölden's unique mix of sport and entertainment worldwide.'The additions join Ski Arlberg, a mountain resort with pre-existing Epic Pass access, alongside several other European ski resorts. At the Swiss resorts of Crans-Montana and Andermatt-Sedrun-Disentis, Epic Pass holders have unlimited access. Epic Pass access to other European mountains varies from destination to destination. In total, with the Epic Pass, skiers can now visit 34 European resorts across ten ski areas (European ski areas, like Andermatt-Sedrun-Disentis, can be conglomerations of multiple mountains). Vail Resorts' expanding European presence furthers a previously-stated strategy for the company. 'Entering the European ski market has been a long-term strategic priority for Vail Resorts,' said Vail Resorts' CEO, Kirsten Lynch, in a 2022 press release.Vail Resorts isn't the only major multi-pass provider to eye Europe.Earlier this year, the sellers of the Ikon Pass, Alterra Mountain Company, announced that Ischgl, Austria, had been added to the Ikon Pass, marking the multi-pass' seventh European destination. The Indy Pass, which focuses on independent ski areas, provides access to a handful of European mountains, too, like Skiwelt, Austria, and Pila, Italy.The Epic Pass Added Six Large Austrian Ski Resorts in the Past Week first appeared on Powder on May 27, 2025

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

an hour ago

• Business Insider

Women are getting wealthier — and they don't invest the same way as men

Women are becoming richer, and they're changing the face of wealth. According to a report by McKinsey published last month, women control about a third of all retail financial assets in the US and the European Union. By 2030, that proportion is expected to rise to between 40% to 45%, wrote Cristina Catania, global co-convener and European lead for the risk and resilience practice, and Jill Zucker, senior partner and co-leader of McKinsey's global growth transformation service line. The report is based on a survey of about 13,000 American and European investors, nearly half of whom were female financial decision makers. It found that between 2018 and 2023, global wealth rose by 43%, but jumped by 51% for women. Women's expanding control of assets is being driven by a combination of factors, including a continuing decline in marriage rates, the ongoing boost in women's average earnings, demographic trends like longer life expectancies, and a broad shift in attitudes about women managing their own finances. Risk doesn't equal reward As women become wealthier through investing, it's becoming clearer that they don't approach it the same way as men. "Women are much more risk-aware," Anna-Sophie Hartvigsen, cofounder of financial education and investment platform Female Invest, told Business Insider. "I would like to call it much more realistic in their own ability to invest." She said women are less likely than men to invest emotionally. "On average, men trade a lot more often than women because they believe they can beat the market or they read something in the news, and they get pumped up or afraid, and then they invest based on that," Hartvigsen said. Female investors, in her view, tend to be more calm, more realistic, and better at assessing risk. However, Katie Geery, an advisor at Rise Private Wealth Management, says being more cautious can also hold women back by leading them to miss out on opportunities to build wealth. "It is important to work with a trusted financial advisor who understands your risk tolerance and can walk you through making well-educated investment decisions based on your long-term goals," she told BI. Returns aren't everything The aims of investing also sometimes differ between men and women. "Women prefer to invest toward achieving specific goals rather than chasing the highest returns," said Avanti Shetye, financial planner at Wealthwyzr. Geery said female investors tend to be more focused on philanthropy and gifting. They often consider their values when buying stock and want their purchases to help make a better impact on the world. "Women often seek financial advisors who are empathetic and take the time to get to know them on a more personal level to gain a deeper understanding of their goals and values," she said. On Female Invest, Hartvigsen said the principles its members care about the most include climate, especially a firm's carbon footprint, and diversity in leadership, in terms of a board having a good gender balance. Start investing early For Shetye, it's important to start investing early. "Women tend to be primary caregivers for children or aging parents and often take unpaid time off," she said. "Not only that, women statistically live longer than men, which implies that women would need to invest as much as they can as early as possible so that their portfolios last them through retirement." Hartvigsen said long-term financial planning is vital: "When you do that, it doesn't matter what happens today." Both agree that this plan should be grounded in expert advice. "Working with a financial planner whose planning process is rooted in financial education can help provide comfort and security to stay consistent even in the roughest of markets," Shetye said. But she also believes that practice is more important than perfection. "You are never going to know everything there is to know about investing," Shetye said. "The key is consistency, and time will do the heavy lifting." Hartvigsen advises her clients to invest monthly on the same day and to diversify their investments. "If you do that, historically, it has been near impossible not to make money in the long run."

USA Today

an hour ago

• USA Today

FIFA Club World Cup: How to watch Manchester City vs Al Ain on Sunday

Manchester City opened its Club World Cup campaign with a comfortable win, and will be heavy favorites again on Sunday against Al Ain. The Club World Cup is using an expanded format for the first time in 2025, with 32 teams from across the world split into eight groups of four teams each. European powerhouses like Bayern Munich, Real Madrid, Manchester City and Chelsea will be taking on winners of previous competitions across CONCACAF, Africa, Asia and South America. Here's how to watch the game: How to watch Manchester City vs Al Ain in the Club World Cup Sunday's game will air on TNT and truTV, and can be streamed for free via DAZN. Stream the Club World Cup on DAZN What time does Manchester City vs Al Ain start? Manchester City vs Al Ain kicks off at 9 p.m. ET at Mercedes-Benz Stadium in Atlanta, Georgia. 2025 FIFA Club World Cup schedule Group stage: June 14 to June 26 Round of 16: June 28 to July 1 Quarterfinals: July 4 to July 5 Semifinals: July 8 to July 9 Final: July 13th 2025 FIFA Club World Cup groups Group A: Palmeiras, Porto, Al Ahly, Inter Miami Group B: Paris Saint-Germain, Atletico Madrid, Botafogo, Seattle Sounders FC Group C: Bayern Munich, Auckland City, Boca Juniors, Benfica Group D: Flamengo, Esperance de Tunis, Chelsea, Los Angeles FC Group E: River Plate, Urawa Red Diamonds, Monterrey, Inter Milan Group F: Fluminese, Borussia Dortmund, Ulsan HD, Mamelodi Sundowns Group G: Manchester City, Wydad AC, Al Ain, Juventus Group H: Real Madrid, Al-Hilal, Pachuca, Red Bull Salzburg

The Hill

an hour ago

• The Hill

Food and Drug Administration staff cuts may hinder US biomedical innovation

President Trump has rightly emphasized restoring America's economic and strategic independence — from reshoring pharmaceutical production to cutting regulatory red tape. But not all reforms are created equal. Recent restructuring efforts at the Food and Drug Administration may have been well-intentioned, but they risk undermining the very innovation and domestic capacity the president seeks to promote. In March, Health and Human Services Secretary Robert F. Kennedy Jr. announced a sweeping reorganization of the agency, which in part included the elimination of 3,500 full-time employees at the Food and Drug Administration — many of them senior scientific staff and experienced regulators who served as institutional pillars across drug review divisions. While we all support government efficiency and the secretary's efforts to create a gold-standard regulatory agency, the loss of this institutional memory risks hobbling the expedited pathways that small biotech firms rely on to deliver therapies for rare and life-threatening diseases. Unfortunately, the impact of these cuts is not theoretical. The Wall Street Journal has reported that some biotech firms have had to delay or cancel clinical trials due to lack of timely Food and Drug Administration guidance. One California biotech firm facing unpredictable delays has even turned to European regulators to move forward with a clinical trial — effectively offshoring American capital, investment and jobs. Others have reported receiving conflicting and confusing feedback from inexperienced FDA staff or no response at all on time-sensitive requests. But such issues don't just affect companies; they hurt patients, too. Innovation in gene therapies, cancer immunotherapies, and treatments for rare diseases depend on regulatory clarity and speed. Without senior staff to help clarify agency positions, decisions are either delayed or driven by less-experienced personnel unfamiliar with long-standing scientific standards. It's no surprise then that over 200 biotech CEOs, patient advocates and investors — many of them strong supporters of FDA modernization — have expressed their concerns in a letter to Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy (R-La.). As a former member of Congress who sat on the Appropriations subcommittee overseeing the FDA, I have long supported targeted reforms to make the agency more nimble and responsive. But there is a fine line between streamlining operations and cutting the institutional capacity necessary to do the job. Removing experienced drug reviewers before an adequate backup plan can be put into place not only jeopardizes U.S. safety standards but also undermines our competitive edge. This matter is not merely a domestic problem; it's a global race. Since 2014, the number of biomedical drugs under development in China has grown twelvefold. Meanwhile, innovation in the U.S. has remained relatively flat. If trends continue, China could match or surpass the U.S. in biomedical innovation within the decade. We have seen this movie before — in semiconductors, in telecommunications, in clean energy. We cannot afford to let biotech go the same way. The Trump administration's tariff policy was designed to bring pharmaceutical manufacturing back to U.S. shores. But how can we expect capital to stay in the U.S. if our regulatory infrastructure cannot deliver? Delays and unpredictability at the FDA don't just slow down science — they push investors to look elsewhere. Even the user fee system — critical to funding timely drug reviews and a source of government revenue — has been impacted by the reduction in force. Staff who oversaw the reauthorization of the Prescription Drug User Fee Act have been laid off, raising questions about whether the agency will even be able to continue to collect user fees and whether these government cuts will actually end up costing taxpayers in the long run. Of course, Kennedy has long been a vocal advocate for health reform. His Make America Healthy Again agenda's focus on combatting chronic diseases and enhancing nutritional standards deserves attention. His focus for such reform is where his background and passion can lead to meaningful improvements. But when it comes to regulating complex biologics and therapeutics, we must be careful about taking actions that could inadvertently stymie scientific progress. President Trump's vision for American self-reliance will only succeed if it's built on a foundation of regulatory competence and stability. Swift actions should therefore be taken to restore the FDA's core functions, rehire critical staff and unfreeze the hiring of roles essential to America's leadership in biomedical science. The stakes — for patients, for innovation and for national security — are simply too high to ignore. John T. Doolittle is a former member of Congress who served on the Agriculture, Rural Development, FDA, and Related Agencies subcommittee of the Committee on Appropriations.